Covid 19 Research using Clinical Trials (Home Page)
Report for D001327: Autoimmune Diseases NIH
(Synonyms: Autoim, Autoimmune, Autoimmune Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug155 | COVID-19 diagnostic test Wiki | 0.71 |
| drug669 | Questionnaire by phone call Wiki | 0.71 |
| drug148 | COVID 19 diagnostic test by PCR Wiki | 0.71 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012213 | Rheumatic Fever NIH | 0.71 |
| D012859 | Sjogren's Syndrome NIH | 0.71 |
| D003095 | Collagen Diseases NIH | 0.50 |
| D015535 | Arthritis, Psoriatic NIH | 0.50 |
| D012216 | Rheumatic Diseases NIH | 0.50 |
| D001168 | Arthritis NIH | 0.41 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.41 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.
NCT04345159 SARS-CoV-2 Systemic Lupus Erythematosus Rheumatoid Arthritis Sjogren's Syndrome Psoriatic Arthritis Other: Questionnaire by phone call MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus
Primary Outcomes
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusion
2 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study
Primary Outcomes
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusionSince December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.
NCT04353609 Sars-CoV2 Chronic Inflammatory Rheumatism Autoimmune Diseases MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
HPO:Autoimmunity
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19
Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19
Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
HPO Nodes
HP:0002960: Autoimmunity
Genes 223
DDX41 PTPN2 LACC1 MS4A1 FASLG LIG4 NFKB2 CASP10 STAT4 TCIRG1 POU2AF1 STOX1 TREX1 RFX5 WIPF1 RASGRP1 ITPR3 PRKCD C1GALT1C1 TNFRSF13B SERPING1 TBX1 PTPN22 STAT4 PEPD IL2RB POLG HLA-DRB1 GFI1 NBN ANKRD55 PTPN22 ANKRD55 TNFSF15 ICOS RFXANK TNFSF12 IFNGR1 C3 HLA-DQB1 FAS ITCH TNFAIP3 NRAS RFXAP TTC7A IL2RB IRF5 GPR35 SERPING1 STAT1 HLA-DPA1 CASP10 HLA-DRB1 SLC7A7 HIRA TNFRSF13B KDM6A SERPING1 CD3G DNASE1L3 ADA KMT2D SMPD1 CIITA HLA-DPB1 STAT4 LCK PRSS1 ICOS ITK IFIH1 CTLA4 PLCG2 HLA-DRB1 DNASE1 C1QC CSF2RA RAG1 CCR6 SPIB ARVCF RAG2 GALC TNFRSF13C ITCH DNASE1L3 MST1 SEC24C IL6 FCGR2A IL2RG PNP CR2 ADA JMJD1C MASP2 IL12RB1 IL2RB MMEL1 ZAP70 COMT UFD1 NBN STAT3 TNPO3 KRAS CD19 TREX1 TBX2 RAG1 AIRE HLA-DRB1 CORIN PTPN22 LMNB2 C1QB RAG1 TRAC SRP54 NHEJ1 FOXP3 TPP2 LRBA CCR6 HAVCR2 MMP2 FOXD3 CD247 TNFRSF13B MIF C1R GP1BB HNF1A DCLRE1C FAS ICOS CTLA4 CAV1 IL7R IRF5 CSF2RB TTC7A FCGR2B CAV1 SPP1 TNFRSF13C CTLA4 FADD CTLA4 IL7R C8A C1R ARHGEF1 RNASEH2B CD19 CR2 STAT1 FOXP3 CCN2 WAS IL2RA IL6 PTPN22 ADA2 PRKCD CCN2 ACP5 C2 SLC12A3 CFTR MTHFD1 C4A ADA2 PGM3 CHD7 KIAA0319L ADAR RREB1 RNASEH2C PTPN22 C1QA TCF4 IL12A RNASEH2A CD247 BTK FCGR2C ADA2 FAS C1QA CD81 PAX4 RAG2 C1S IRAK1 PRKCD ELANE TREX1 NFKB1 ZAP70 SEC23B NLRP1 PTEN TNFSF12 FLT1 ADA FASLG PIK3R1 STIM1 IRF5 CLCNKB IL2RA CTRC PRTN3 IL2RA TBX1 RMRP SPINK1 SAMHD1 PTPN2 NFKB2 DCLRE1C SNP 0
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)